- Home
- Publications
- Publication Search
- Publication Details
Title
An overview on the current status of cancer nanomedicines
Authors
Keywords
-
Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume 34, Issue 5, Pages 911-921
Publisher
Informa UK Limited
Online
2017-12-26
DOI
10.1080/03007995.2017.1421528
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Assessment of chemotherapy on various biochemical markers in breast cancer patients
- (2017) Márcia F. C. J. Paz et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy
- (2017) Emma Kipps et al. Therapeutic Advances in Medical Oncology
- Liposomal Formulations in Clinical Use: An Updated Review
- (2017) Upendra Bulbake et al. Pharmaceutics
- Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
- (2016) E. González-Barca et al. ANNALS OF HEMATOLOGY
- Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma
- (2016) J Hochberg et al. BONE MARROW TRANSPLANTATION
- Lipid based noninvasive vesicular formulation of cytarabine: Nanodeformable liposomes
- (2016) Rakesh Raj et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future
- (2016) Truffi Marta et al. Journal of Nanomaterials
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma
- (2015) Amandine Segot et al. ANNALS OF HEMATOLOGY
- Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
- (2015) T. C. Chang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)
- (2015) Jasgit C Sachdev et al. CANCER RESEARCH
- Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics
- (2015) Sophie Marchal et al. DRUGS
- Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers
- (2015) Wojciech Jurczak et al. MEDICAL ONCOLOGY
- Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis
- (2015) Franziska Jahn et al. ONCOLOGY
- Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting
- (2015) Aman P. Mann et al. Oncotarget
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
- (2014) J. E. Lancet et al. BLOOD
- Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
- (2014) Jorge E. Cortes et al. CANCER
- Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
- (2014) N. Casagrande et al. CLINICAL CANCER RESEARCH
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation
- (2014) Sandeep Hedgire et al. International Journal of Nanomedicine
- State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines
- (2014) Charlene M. Dawidczyk et al. JOURNAL OF CONTROLLED RELEASE
- Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
- (2014) W Du et al. ONCOGENE
- Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
- (2014) Y Aye et al. ONCOGENE
- Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer
- (2014) YAJUN GUO et al. Oncology Letters
- Doxorubicin, DNA torsion, and chromatin dynamics
- (2013) Fan Yang et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
- (2013) A H Ko et al. BRITISH JOURNAL OF CANCER
- Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer
- (2013) Naike Casagrande et al. GYNECOLOGIC ONCOLOGY
- Cancer Chemoprevention by Polyphenols and Their Potential Application as Nanomedicine
- (2013) SHAMS TABREZ et al. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: A Demonstration of the Super-Enhanced Permeability and Retention Effect after Photoimmunotherapy
- (2013) K. Sano et al. MOLECULAR CANCER THERAPEUTICS
- Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL
- (2013) B. T. Farrell et al. NEUROLOGY
- Functionalized mesoporous silicon for targeted-drug-delivery
- (2012) Ozra Tabasi et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
- (2012) Stephanie D. Steichen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer
- (2012) Valentina Guarneri et al. EXPERT OPINION ON PHARMACOTHERAPY
- Challenges to effective cancer nanotheranostics
- (2012) Marites P. Melancon et al. JOURNAL OF CONTROLLED RELEASE
- Polyvalent Dendrimer-Methotrexate as a Folate Receptor-Targeted Cancer Therapeutic
- (2012) Thommey P. Thomas et al. MOLECULAR PHARMACEUTICS
- Nanoparticle Delivery of Cancer Drugs
- (2011) Andrew Z. Wang et al. Annual Review of Medicine
- Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma
- (2011) Hongliang Xin et al. BIOMATERIALS
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Anthracyclines in the management of metastatic breast cancer: state of the art
- (2011) Alessandra Gennari et al. EJC SUPPLEMENTS
- Expert opinion: Responsive polymer nanoparticles in cancer therapy
- (2011) William B. Liechty et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
- (2011) Eric J. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma
- (2011) Matteo Dell'olio et al. LEUKEMIA & LYMPHOMA
- Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma
- (2010) Michele Spina et al. CANCER
- Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
- (2010) S. K. Libutti et al. CLINICAL CANCER RESEARCH
- Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia
- (2010) Susan O'Brien et al. Clinical Lymphoma Myeloma & Leukemia
- Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma
- (2010) N. Gokbuget et al. HAEMATOLOGICA
- Concurrent Liposomal Cisplatin (Lipoplatin), 5-Fluorouracil and Radiotherapy for the Treatment of Locally Advanced Gastric Cancer: A Phase I/II Study
- (2010) Michael I. Koukourakis et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Targeted nanodelivery of drugs and diagnostics
- (2010) Margaret A. Phillips et al. Nano Today
- Impact of Nanotechnology on Drug Delivery
- (2009) Omid C. Farokhzad et al. ACS Nano
- Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)
- (2009) R.C.F. Leonard et al. BREAST
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma
- (2009) Jose A. Garcia-Marco et al. CANCER
- A liposome-based nanostructure for aptamer directed delivery
- (2009) Huaizhi Kang et al. CHEMICAL COMMUNICATIONS
- A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors
- (2009) Daniel Morgensztern et al. CHEMOTHERAPY
- Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
- (2009) Teni Boulikas EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer
- (2009) Ronnie TP Poon et al. EXPERT OPINION ON PHARMACOTHERAPY
- Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer
- (2009) N. Mylonakis et al. LUNG CANCER
- Nanoparticle therapeutics: a personal perspective
- (2009) Scott E. McNeil Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Active targeting schemes for nanoparticle systems in cancer therapeutics
- (2008) James D. Byrne et al. ADVANCED DRUG DELIVERY REVIEWS
- Protein nanoparticles as drug carriers in clinical medicine
- (2008) Michael J. Hawkins et al. ADVANCED DRUG DELIVERY REVIEWS
- Liposomal daunorubicinversusstandard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia
- (2008) Roberto Latagliata et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in mice
- (2008) Tamer A. Elbayoumi et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
- (2008) Felix Kratz JOURNAL OF CONTROLLED RELEASE
- Intrathecal liposomal cytarabine: More friend than foe?
- (2008) Deepa Bhojwani et al. LEUKEMIA & LYMPHOMA
- In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
- (2008) Paul Tardi et al. LEUKEMIA RESEARCH
- How we got here, where we are going and being a cog in something turning
- (2008) Charles R Martin Nanomedicine
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
- (2008) S. Dhar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search